NF1 c.4778T>C ;(p.F1593S)

Variant ID: 17-29592300-T-C

NM_001042492.2(NF1):c.4778T>C;(p.F1593S)

This variant was identified in 1 publication

View GRCh38 version.




Publications:


Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.

Molecular Cancer
Berlak, Mareike M; Tucker, Elizabeth E; Dorel, Mathurin M; Winkler, Annika A; McGearey, Aleixandria A; Rodriguez-Fos, Elias E; da Costa, Barbara Martins BM; Barker, Karen K; Fyle, Elicia E; Calton, Elizabeth E; Eising, Selma S; Ober, Kim K; Hughes, Deborah D; Koutroumanidou, Eleni E; Carter, Paul P; Stankunaite, Reda R; Proszek, Paula P; Jain, Neha N; Rosswog, Carolina C; Dorado-Garcia, Heathcliff H; Molenaar, Jan Jasper JJ; Hubank, Mike M; Barone, Giuseppe G; Anderson, John J; Lang, Peter P; Deubzer, Hedwig Elisabeth HE; Künkele, Annette A; Fischer, Matthias M; Eggert, Angelika A; Kloft, Charlotte C; Henssen, Anton George AG; Boettcher, Michael M; Hertwig, Falk F; Blüthgen, Nils N; Chesler, Louis L; Schulte, Johannes Hubertus JH
Publication Date: 2022-06-10

Variant appearance in text: NF1: 4778T>C; F1593S
PubMed Link: 35689207
Variant Present in the following documents:
  • Main text
  • 12943_2022_1583_MOESM1_ESM.pdf
View BVdb publication page